{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-014728","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.647258+00:00","generated_at":"2026-05-15T21:27:14.192938+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alnylam grants CEO Greenstreet performance-based PSUs tied to $500-$800 stock price by 2029","bullets":["Target of 55,373 PSUs ($18.0M face value at $325.07 close on grant date).","Vesting requires 30-day avg stock price of $500 (50% vest) to $800 (200% vest) by Dec 31, 2029.","Baseline threshold of $500 exceeds all-time high; award forfeited if price below $500.","Special award granted alongside annual equity, designed with independent compensation consultant.","Under Greenstreet, Alnylam achieved ~100% stockholder return, AMVUTTRA approval, and 2025 profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-014728","json":"https://secwatch.observer/filing/0001628280-26-014728.json","markdown":"https://secwatch.observer/filing/0001628280-26-014728.md","text":"https://secwatch.observer/filing/0001628280-26-014728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026014728/0001628280-26-014728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026014728/alny-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:27:14.192938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}